Articles related to ENDOMETRIAL CANCER
“Unprecedented” PFS Benefit with Selinexor in p53 Wild-Type Endometrial Cancer
Selinexor has demonstrated an extraordinary extension in progression-free survival in patients with wild-type TP53 advanced or recurrent endometrial cancer, according to the recent findings from the SIENDO study.
Obstetrics & Gynecology August 1st 2023
The Link Between Hair Straighteners and Uterine Cancer
According to earlier studies, the usage of some hair products, such as relaxers and pressing products, may raise the risk of ovarian cancer. The usage of hair straighteners may now also be related to uterine cancer, according to a recent study. The CDC lists using birth control pills, working out frequently, maintaining a healthy weight, and taking progesterone as required as factors that lower the risk of uterine cancer.
Obstetrics & Gynecology May 1st 2023
Two “Homerun” Trials Expected to Change Standard for Advanced, Recurrent Endometrial Cancer
Results from the RUBY trial of dostarlimab and the GY018/Keynote-068 of pembrolizumab were presented at the 2023 SGO Annual Meeting on Women’s Cancer in March and were simultaneously published in The New England Journal of Medicine. The studies examined the efficacy and safety of the medications in all individuals and those with mismatch repair deficient (dMMR) illness. Each trial examined a separate PD-1 inhibitor, pembrolizumab or dostarlimab, in combination with chemotherapy in patients with advanced or recurrent endometrial cancer. In individuals with dMMR illness, both medications lowered the chance of disease progression or death by roughly 70%.
Oncology, Medical April 18th 2023